Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Nov 1;7(44):72184-72196.
doi: 10.18632/oncotarget.12360.

Prognostic effect of intratumoral neutrophils across histological subtypes of non-small cell lung cancer

Mehrdad Rakaee  1 , Lill-Tove Busund  1   2 , Erna-Elise Paulsen  3   4 , Elin Richardsen  1   2 , Samer Al-Saad  1   2 , Sigve Andersen  3   4 , Tom Donnem  3   4 , Roy M Bremnes  3   4 , Thomas K Kilvaer  3   4
Affiliations

Prognostic effect of intratumoral neutrophils across histological subtypes of non-small cell lung cancer

Mehrdad Rakaee et al. Oncotarget. .

Abstract

Recent data indicate that tumor-associated neutrophils (TANs) serve a dual role in tumor progression and regression. CD66b is a neutrophil marker and has been associated with patient outcome in various cancers. However, its clinical impact in non-small cell lung cancer (NSCLC) remains controversial. 536 NSCLC patients, of which 172 harbored lymph node metastases, were included in this study. Tissue microarrays were constructed and multiplexed immunohistochemistry of CD66b, CD34 and pan-keratin was performed to evaluate the localization and quantity of CD66b+ TANs. High intratumoral CD66b+ TANs density in squamous cell carcinoma (SCC) subgroup was an independent positive prognosticator for disease-specific survival (P = 0.038). In contrast, high intratumoral TANs density was an independent negative prognostic factor in the adenocarcinoma (ADC) subgroup (P= 0.032). Likewise, in ADC patients with lymph node metastases, high level of intratumoral TANs was associated with poor prognosis (P = 0.003). Stromal CD66b+ TANs were not associated with outcome of NSCLC patients. In conclusion, CD66b+ TANs show diverging prognostic effect in NSCLC patients according to histological subgroups. The presence of CD66b+ TANs could prove pivotal for development of an immunoscore in ADC NSCLC patients.

Keywords: CD66b; NSCLC; TANs; lung cancer; neutrophils.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
A. Scoring assessment guideline. Scoring of intratumoral (tumor nest) and stromal CD66b+ neutrophils was conducted utilizing the following exclusion- and inclusion-criteria. In intratumoral assessment, we have included only unaggregated CD66b+ cells completely surrounded by tumor epithelial cells. Stromal assessment only regarded extravascular CD66b+ cells. The excluded areas consisted of intratumoral and stromal aggregates of neutrophils, intravascular neutrophils and CD66b+ cells with granular background in stroma. Especially in SCC tissue, the central tumor zone often had dense granular CD66+ structures with some CD66b+ cells, considered a pre- or necrotic area, which were excluded from scoring. B. Multiplexed IHC analysis of TANs with CD66b/CD34/pan-CK panel, high versus low intratumoral densities. Brown, purple and yellow substrates were applied to visualize CD66b, CD34 and pan-CK respectively (magnification 10x, 20x).
Figure 2
Figure 2. Disease-specific survival curves for
A. Intratumoral CD66b in the overall cohort (OC) of primary tumors (PT); B. Intratumoral CD66b in squamous cell carcinomas (SCC) of PT; C. Intratumoral CD66b in adenocarcinomas (ADC) of PT; D. Stromal CD66b in the overall cohort of PT; E. Stromal CD66b in SCC of PT; F. Stromal CD66b in ADC of PT; G. Intratumoral CD66b in the overall cohort of LN+; H. Intratumoral CD66b in SCC of LN+; I. Intratumoral CD66b in ADC of LN+
See this image and copyright information in PMC

References

    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-tieulent J, Jemal A. Global Cancer Statistics, 2012. CA a cancer J Clin. 2015;65:87–108. - PubMed
    1. Edwards BK, Noone A-M, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, Jemal A, Cho H, Anderson RN, Kohler BA, Eheman CR, Ward EM. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120:1290–314. - PMC - PubMed
    1. Remark R, Becker C, Gomez JE, Damotte D, Dieu-Nosjean M-C, Sautès-Fridman C, Fridman W-H, Powell C a, Altorki NK, Merad M, Gnjatic S. The Non–Small Cell Lung Cancer Immune Contexture. A Major Determinant of Tumor Characteristics and Patient Outcome. Am J Respir Crit Care Med. 2015;191:377–90. - PMC - PubMed
    1. Gregory a D, McGarry Houghton a. Tumor-Associated Neutrophils: New Targets for Cancer Therapy. Cancer Res. 2011;71:2411–6. - PubMed
    1. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SM. Cancer Cell. Vol. 16. Elsevier Ltd; 2009. Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN; pp. 183–94. - PMC - PubMed

MeSH terms